Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti-lymphoma activity, their use after transplantation may lead to a decreased risk of relapse and hence better transplantation outcome.

Further Study Information

• Because no one knows which of the study options is best, participants will be "randomized" into one of the two possible groups for GVHD prophylaxis: 1) a sirolimus-containing regimen (tacrolimus, sirolimus and methotrexate) or 2) a sirolimus-free regimen (tacrolimus and methotrexate or cyclosporine and mycophenolate mofetil).

• Participants will receive a reduced intensity conditioning regimen. This is done to prepare the body for transplantation. This will consist of a combination of drugs (either fludarabine and busulfan or fludarabine, cyclophosphamide and low-dose total body irradiation). The purpose of these drugs is to weaken the immune system and lower the chance of the body rejecting the donated stem cells.

• Participants will also receive the GVHD prophylaxis regimen that they have been randomized to. These drugs will lower the chance of rejecting the donor cells and lower the chance of developing GVHD.

Eligibility Criteria

Inclusion Criteria:

• Patients will be eligible if their primary indication for transplantation is among the following: Indolent B-cell non-Hodgkin lymphoma (NHL); Aggressive B-Cell NHL; T-cell NHL; or Hodgkin Lymphoma.

• Patients must have one of the following combinations of disease status and disease histology at the time of enrollment: 1) Patients may be transplanted as part of first-line therapy if they have one of the following histologies: CLL with adverse cytogenetics, MCL or, T-cell NHL. 2) Patients may be transplanted as part of treatment for relapsed or refractory disease without a prior autologous transplantation of they have one of the following histologies: Indolent NHL (including CLL/SLL), MCL or T-cell NHL. 3) Patients may be transplanted as part of treatment for disease that has relapsed or progressed after autologous transplantation if they have any of the histologies listed above. Patients may also be enrolled without a prior autologous transplantation if they have a contraindication to autologous transplantation, in the opinion of the treating clinician. 4) There is no minimal or maximal time interval from the patient's last anti-lymphoma therapy and the time of transplantation.

• 18-72 years of age

• Matched related or matched unrelated donor

• Donor willing to donate peripheral blood stem cells and meeting institutional criteria for stem cell donation. The donor must be medically eligible to donate stem cells according to individual transplant center criteria.

Exclusion Criteria:

• Patients with Burkitt lymphoma or DLBCL with a c-myc rearrangement

• Karnofsky performance status of less than 70% at the time of registration

• Prior allogeneic stem cell transplantation (note that prior autologous stem cell transplantation is allowed)

• Uncontrolled infection

• Serum creatinine 2.0mg/dl or greater

• Total bilirubin 2.0mg/dl or greater (unless related to hemolysis or Gilbert's syndrome)

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3 times or greater than the institutional upper limit of normal

• Left ventricular ejection fraction < 30%

• Cholesterol > 500mg/dl or triglycerides > 500 mg/dl despite appropriate treatment

• Seropositivity for HIV

• Pregnancy or breast-feeding (effective contraception must be used during therapy and for at least 6 months after the end of immunosuppressive agents)

• Prior history of allergy to sirolimus, tacrolimus, cyclosporine, methotrexate or MMF

• Concomitant treatment with another investigational drug (unless cleared by study chair)

Trial Contact Information

Trial Lead Organizations/Sponsors

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute

Philippe Armand, MD, PhD

Principal Investigator

Philippe Armand, MD, PhD		Ph: 617-632-2305
		Email: parmand@partners.org

U.S.A.
Massachusetts
	Boston
	Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
		Susan Stephenson, RN, OCN	Ph: 617-632-5137
			Email: slstepehnson@partners.org
		Marie-Michele Sainvil, BA	Ph: 617-632-5626
			Email: msainvil@partners.org
		Philippe Armand, MD, PhD	Principal Investigator
	Massachusetts General Hospital
		Yi-Ben Chen, MD	Ph: 617-726-1124
			Email: yachen@partners.org
		JoAnne Kennedy, RN	Ph: 617-726-6034
			Email: JKennedy9@partners.org
		Yi-Ben Chen, MD	Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00928018
Information obtained from ClinicalTrials.gov on September 03, 2012

Back to Top